Companies / Switzerland
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Novartis Receives Go-Ahead For New Products
November 2006 | Product LaunchSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
The EU Committee for Medicinal Products (CHMP) has recommended that Swiss firm Novartis' Exforge (amlodipine + valsartan) and Lucentis (ranibizumab) receive approval for hypertension and age-related macular degeneration (AMD), respectively. However, the committee has turned down the company's Mycograb (anti-HSP90 antibody) submission for fungal infections because of manufacturing issues. Despite the negative Mycograb ruling, BMI expects Novartis to address the CHMP's concerns and believes that the agent will eventually receive approval due to its impressive performance in clinical trials. If launched, the three medicines will prove to be important growth drivers for